Table 1 Demographic and clinical characteristics of the participants.
Variables | Total | Post-treatment hepatotoxicity (−) | Post-treatment hepatotoxicity (+) | P-value |
|---|---|---|---|---|
(n, %) | 452 | 359 (79.42) | 93 (20.58) | |
Age (years) | 57.00 ± 17.00 | 58.00 ± 17.00 | 55.00 ± 16.00 | 0.153 |
Hypertension (n, %) | 149 (32.96) | 121 (33.70) | 28 (30.11) | 0.511 |
Diabetes mellitus (n, %) | 77 (17.04) | 63 (17.55) | 14 (15.05) | 0.568 |
Hyperlipidemia (n, %) | 22 (4.87) | 16 (4.46) | 6 (6.45) | 0.599 |
Liver underlying disease (n, %) | 44 (9.73) | 33 (9.19) | 11 (11.83) | 0.445 |
Combined chemo-radiation (n, %) | 93 (20.58) | 74 (20.61) | 19 (20.43) | 0.969 |
Past history of hepatotoxicity (+) (n, %) | 169 (37.39) | 119 (33.15) | 50 (53.76) | < 0.001 |
Tumor type (n, %) | 0.275 | |||
Cervix cancer | 210 (46.46) | 165 (45.96) | 45 (48.39) | |
Ovary cancer | 182 (40.27) | 141 (39.28) | 41 (44.09) | |
Endometrial cancer | 34 (7.52) | 29 (8.08) | 5 (5.38) | |
Other types of gynecological cancer | 26 (5.75) | 24 (6.69) | 2 (2.15) | |
Combinations of chemotherapeutic drugs (n, %) | 0.016 | |||
PLPB group | 211 (46.68) | 175 (48.75) | 36 (38.71) | |
CPPB group | 108 (23.89) | 74 (20.61) | 34 (36.56) | |
PPB group | 38 (8.41) | 31 (8.64) | 7 (7.53) | |
OCCD group | 95 (21.02) | 79 (22.01) | 16 (17.20) | |
Duration of chemotherapy drugs (n, %) | 0.011 | |||
1 day | 147 (32.52) | 124 (34.54) | 23 (24.73) | |
2 days | 171 (37.83) | 136 (37.88) | 35 (37.63) | |
3 days | 73 (16.15) | 48 (13.37) | 25 (26.88) | |
≥ 4 days | 61 (13.50) | 51 (14.21) | 10 (10.75) | |
TI with different prevention days (n, %) | 0.692 | |||
1 day | 25 (5.53) | 17 (4.74) | 8 (8.60) | |
2 days | 101 (22.35) | 82 (22.84) | 19 (20.43) | |
3 days | 151 (33.41) | 121 (33.70) | 30 (32.26) | |
4 days | 98 (21.68) | 78 (21.73) | 20 (21.51) | |
≥ 5 days | 77 (17.04) | 61 (16.99) | 16 (17.20) |
